Crohn’s Disease (Regional Enteritis) is an indication for drug development with over 240 pipeline drugs currently active. According to GlobalData, preregistered drugs for Crohn’s Disease (Regional Enteritis) have a 95.83% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Crohn’s Disease (Regional Enteritis) compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Crohn’s Disease (Regional Enteritis) overview

Crohn’s Disease, also known as regional enteritis, is a chronic inflammatory bowel disease characterized by inflammation of the digestive tract lining. It can affect any part of the gastrointestinal tract from the mouth to the anus, typically manifesting in the ileum and colon. Symptoms include abdominal pain, diarrhea, fatigue, weight loss, and malnutrition. The exact cause of Crohn’s Disease remains unknown, but it’s believed to involve a combination of genetic, environmental, and immune factors. Treatment aims to alleviate symptoms, induce remission, and prevent complications through medication, dietary changes, and in severe cases, surgery to remove affected portions of the intestine.

For a complete picture of PTSR and LoA scores for drugs in Crohn’s Disease (Regional Enteritis), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.